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The Antenatal Corticosteroids Trial (ACT): a
secondary analysis to explore site
differences in a multi-country trial
Karen Klein1*, Elizabeth M. McClure2, Daniela Colaci1, Vanessa Thorsten2, Patricia L. Hibberd3, Fabian Esamai4,
Ana Garces5, Archana Patel6, Sarah Saleem7, Omrana Pasha7, Elwyn Chomba8, Waldemar A. Carlo9,
Nancy F. Krebs10, Shivaprasad Goudar11, Richard J. Derman12, Edward A Liechty13, Marion Koso-Thomas14,
Pierre M. Buekens15, José M. Belizán1, Robert L. Goldenberg16 and Fernando Althabe1

Abstract
Background: The Antenatal Corticosteroid Trial (ACT) assessed the feasibility, effectiveness, and safety of a multifaceted
intervention to increase the use of antenatal corticosteroids (ACS) in mothers at risk of preterm birth at all levels of care
in low and middle-income countries. The intervention effectively increased the use of ACS but had no overall impact on
neonatal mortality in the targeted <5th percentile birth weight infants. Being in the intervention clusters was also
associated with an overall increase in neonatal deaths. We sought to explore plausible pathways through which this
intervention increased neonatal mortality.
Methods: We conducted secondary analyses to assess site differences in outcome and potential explanations for the
differences in outcomes if found. By site, and in the intervention and control clusters, we evaluated characteristics of the
mothers and care systems, the proportion of the <5th percentile infants and the overall population that received ACS,
the rates of possible severe bacterial infection (pSBI), determined from clinical signs, and neonatal mortality rates.
Results: There were substantial differences between the sites in both participant and health system characteristics, with
Guatemala and Argentina generally having the highest levels of care. In some sites there were substantial differences in
the health system characteristics between the intervention and control clusters. The increase in ACS in the intervention
clusters was similar among the sites. While overall, there was no difference in neonatal mortality among <5th percentile
births between the intervention and control clusters, Guatemala and Pakistan both had significant reductions in neonatal
mortality in the <5th percentile infants in the intervention clusters. The improvement in neonatal mortality in the
Guatemalan site in the <5th percentile infants was associated with a higher level of care at the site and an
improvement in care in the intervention clusters. There was a significant increase overall in neonatal mortality in
the intervention clusters compared to the control. Across sites, this increase in neonatal mortality was statistically
significant and most apparent in the African sites. This increase in neonatal mortality was accompanied by a
significant increase in pSBI in the African sites.
(Continued on next page)
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Conclusions: The improvement in neonatal mortality in the Guatemalan site in the <5th percentile infants was
associated with a higher level of care and an improvement in care in the intervention clusters. The increase in
neonatal mortality in the intervention clusters across all sites was largely driven by the poorer outcomes in the
African sites, which also had an increase in pSBI in the intervention clusters. We emphasize that these results
come from secondary analyses. Additional prospective studies are needed to assess the effectiveness and safety
of ACS on neonatal health in low resource settings.
Trial registration: Trial registration: clinicaltrials.gov (NCT01084096)

Background
The use of antenatal corticosteroids (ACS) is believed to
be among the most effective interventions to reduce
neonatal mortality associated with preterm birth. However, the majority of research on its efficacy and safety
has been conducted in high-resource settings [1–6]. Few
studies on ACS were conducted in low-middle income
countries (LMIC) where the overwhelming majority of
deaths associated with preterm birth occur [7–9]. Of
those studies which have been performed outside of developed countries, several have been in Latin America,
with only a few in Asia or Africa and none in the regions
of the highest burden of mortality [10–12].
The Global Network Antenatal Corticosteroid Trial
(ACT), was a multi-country cluster randomized trial to assess the feasibility, effectiveness, and safety of a multifaceted
intervention developed to increase the use of ACS at all
levels of health care in LMICs [13, 14]. ACT, which was
conducted in seven rural and semi-urban sites in subSaharan Africa, Asia and Latin America, showed that the
intervention increased ACS use in the intervention clusters
(46 % vs.10 % in women with <5th percentile birth weight
live births), but it was not associated with a reduction in
neonatal mortality in the targeted <5th percentile infants in
the intervention clusters. An unexpected finding was that
overall neonatal mortality was higher in intervention
clusters, with the excess mortality occurring in infants
born at >25th percentile site-specific birth weights.
Since ACT was a multi-country intervention, we sought
to explore whether regional differences were associated
with the impact of the ACS intervention. ACT was pragmatic in design and there was limited data collection beyond the primary study outcomes. Thus, the ability to
identify site specific associations is limited. Nonetheless,
given that ACT is the largest trial of ACS use in lowincome countries and the unanticipated results, in this
paper, we further explore neonatal outcomes by site.
Methods
Specific aims

The objectives of this secondary analysis were: 1) to describe the effects of the ACT intervention on neonatal
mortality, use of ACS, and possible severe neonatal

bacterial infection (pSBI) by site; and 2) to assess whether
the observed differences were correlated with either the
use of ACS, differences in maternal characteristics or in
aspects related to care.
Study design and participants

This is a secondary analysis of data collected during the
ACT. The study intervention and methods are described
in detail elsewhere [13]. Briefly, the ACT was a two-arm,
cluster-randomized trial conducted in seven sites of the
Global Network for Women’s and Children’s Health Research (Argentina, Guatemala, Zambia, Kenya, Pakistan,
Belgaum (India) and Nagpur (India)). Clusters were organized into strata based on the 28-day neonatal mortality
rate by site, and then randomized by the data center (RTI
International, Durham, NC, USA). Intervention clusters received a multifaceted intervention (health provider training,
posters, pregnancy discs, uterine height tape, and antenatal
corticosteroids kits). Providers in the intervention clusters
were trained to administer one course of four doses of
6 mg of dexamethasone every 12 h to women identified at
high-risk of preterm birth. Along with providers in the formal health systems, traditional birth attendants and community health workers were also trained to identify women
at risk and initiate treatment. The intervention period was
18-months, with the start date between 2011 and 2012
varying by site based on the site approval date.
Outcome data were collected by trained registry administrators in a prospective, on-going, population-based maternal and newborn health (MNH) registry independent of
the intervention team. The MNH registry was implemented in 2009 [15, 16] so all sites had at least 1 year of
pretrial data was available. MNH data were collected during pregnancy, following delivery and at 6-weeks postpartum to determine basic information regarding use of
antenatal and delivery care, stillbirth, neonatal mortality
and morbidity. Data were collected on observable infant
signs of illness which were used to determine possible severe bacterial infection (pSBI) based on the World Health
Organization definition, as described in detail elsewhere
[Hibberd PL, Hansen NI, Wang M, et al.: Trends in the
Incidence of Possible Severe Bacterial Infection and Case
Fatality Rates in Rural communities in Sub-Saharan
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Africa, South Asia and Latin America, 2010–2013: A multicenter prospective cohort study, forthcoming; 17, 18]. In
addition, in the intervention clusters, we collected data on
women, newborns and intervention process measures.

Statistical analyses

Generalized linear models were used to evaluate the relationship between covariates and the outcomes of interest (neonatal mortality and pSBI) and to develop point
and interval estimates of relative risk (RR) associated
with those risk factors. Generalized estimating equations
accounted for the correlation of outcomes within cluster
to develop appropriate confidence intervals. Analyses
were adjusted for randomization strata. Models were log
binomial when possible, otherwise Poisson models were
utilized. Pre-trial data were analyzed to assess the status
of various measures prior to trial implementation. All
analyses were done by RTI International with SAS versions 9.3 and 9.4 (SAS Institute, Cary, NC, USA).

Ethical approvals
The trial was reviewed and approved by the ethics
committees at each site. In addition, the World Health
Organization and the Eunice Kennedy Shriver National
Institute of Health and Human Development (NICHD)
reviewed and approved the protocol. A Data Monitoring
Committee reviewed the study enrollment and safety. All
women provided informed consent prior to enrollment.
Results
A total of 99,742 women were enrolled in ACT across
the sites including 62,541 in south Asia, 23,021 in subSaharan Africa, and 14,180 in Latin America. Basic maternal characteristics in the sites, as well as in the treatment
and control clusters are presented for all sites (Table 1).
The percent of women who were age <20 years ranged
from 1.8 % in Nagpur, India to 28.8 % in Argentina. Conversely, the percent of women age >35 years of age ranged
from 0.2 % in Belgaum, India to 10.4 % in the Kenyan site.
Rates of women without any formal education ranged

Table 1 Maternal characteristics by site and by intervention (Int) and control (Ctr) clustersa
South Asia (n = 62,541)
Belgaum, India

Women, N

Nagpur, India

Pakistan

Total

Int

Ctr

Total

Int

Ctr

Total

Int

Ctr

31,530

14,900

16,630

15,095

7,498

7,597

15,916

7,714

8,202

Maternal age, %
< 20

8.7

7.2

10.0

1.8

1.6

2.0

3.9

3.7

4.1

20 - 35

91.1

92.6

89.8

97.9

98.1

97.7

90.1

91.5

88.9

> 35

0.2

0.2

0.1

0.3

0.3

0.3

5.9

4.8

7.0

19.3

20.5

18.3

2.5

3.3

1.9

80.9

81.2

80.3

0

43.7

43.8

43.6

45.9

45.1

46.8

19.8

19.5

20.1

1

34.1

35.2

33.8

42.6

43.0

42.4

20.5

20.9

20.2

2+

21.7

21.0

22.6

11.4

11.9

10.8

59.6

59.6

59.7

No formal school %
Parity, %

Sub-Saharan Africa (n = 23,021)
Zambia

Women, N

Latin America (n = 14,180)
Kenya

Guatemala

Argentina

Total

Int

Ctr

Total

Int

Ctr

Total

Int

Ctr

Total

Int

Ctr

10,018

4,279

5,739

13,003

5,900

7,103

9,773

5,813

3,960

4,407

2,115

2,292

Maternal age, %
< 20

26.7

25.6

27.5

22.6

22.6

22.6

15.8

15.6

16.1

28.8

28.8

28.7

20 - 35

65.8

66.3

65.5

73.4

73.3

73.4

73.8

74.5

72.9

64.2

64.1

64.3

> 35

7.4

8.1

7.0

4.0

4.1

4.0

10.4

10.0

10.9

7.0

7.1

7.0

9.7

9.6

9.8

2.7

2.8

2.6

18.1

16.6

20.5

2.0

2.0

1.9

0

28.8

27.5

29.8

26.4

26.1

26.6

27.6

27.8

27.4

35.4

35.9

35.1

1

20.1

19.9

20.3

22.2

22.4

22.0

21.7

22.1

21.2

24.7

25.0

24.6

2+

51.1

52.6

49.9

51.5

51.5

51.4

50.6

50.1

51.4

39.7

39.1

40.4

No formal school %
Parity, %

a

Denominators include missing values
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from 2.0 % in Argentina to 80.9 % in the Pakistan site.
The highest proportion of women with parity >2 was in
Pakistan, where nearly 60 % of women had 2 or more
prior pregnancies compared to a low of 11.2 % in the Nagpur site. Within the sites, the maternal demographics were
generally similar between the intervention and control
clusters.
Table 2 summarizes the indicators of care for each site
during the trial. Rates of women having at least one
antenatal care (ANC) visit ranged from 88.4 % in
Pakistan to 100 % in Belgaum. The frequency of women

having > 3 ANC visits ranged from 80.4 % of Guatemalan
women to less than 20 % in Zambia. In the Indian sites,
from 75 to 90 % of the women initiated ANC during the
first trimester compared to less than 11 % of women initiating early ANC in the African sites. Around 50 % of the
women in the Latin American sites initiated ANC in
the first trimester. Physician delivery ranged from
74.6 % in Argentina to less than 3 % in both African
sites. Women unattended during delivery, or attended
by a family member only, ranged from <1 % in the Nagpur, Guatemalan and Argentinian sites to as many as

Table 2 Process of care by site and by intervention (Int) and control (Ctr) clusters
South Asia
Belgaum
Total

Nagpur
Int

Ctr

Total

Pakistan
Int

Ctr

Total

Int

Ctr

Deliveries, N

31,530

14,900

16,630

15,095

7,498

7,597

15,916

7,714

8,202

Antenatal care (ANC) received, %

100.0

100.0

99.9

99.9

99.9

99.9

88.4

86.9

89.7

>3 ANC visits

60.8

54.6

66.5

73.1

83.1

63.2

31.1

31.0

31.3

ANC visit in 1st trimester

75.6

70.7

80.0

90.0

85.6

94.4

33.5

32.7

34.2

62.0

56.5

66.9

63.5

48.3

78.4

30.5

34.1

27.1

Delivery attendant, %
Physician
Nurse/nurse midwife

33.6

39.3

28.5

35.2

50.4

20.2

26.3

24.9

27.7

Traditional birth attendant

1.1

1.1

1.1

0.6

0.6

0.6

40.7

37.7

43.5

Family/Unattended

3.4

3.2

3.6

0.7

0.6

0.7

2.5

3.3

1.7

Hospital

71.4

68.1

74.4

70.1

63.4

76.7

33.9

27.6

39.8

Clinic

23.6

27.3

20.3

28.4

35.2

21.7

26.3

31.4

21.4

Home/Other

5.0

4.6

5.3

1.4

1.3

1.6

39.8

40.9

38.8

17.4

16.9

17.9

21.5

20.8

22.3

12.3

11.5

13.1

Delivery location, %

C-section, %

Sub-Saharan Africa

Latin America

Zambia
Total

Kenya
Int

Ctr

Total

Guatemala
Int

Ctr

Total

Int

Argentina
Ctr

Total

Int

Ctr

Deliveries, N

10,018

4,279

5,739

13,003

5,900

7,103

9,773

5,813

3,960

4,407

2,115

2,292

Antenatal care (ANC) received

99.7

99.7

99.6

98.8

98.9

98.7

99.0

98.8

99.2

95.5

96.6

94.6

> 3 ANC Visits

19.6

25.2

15.3

43.2

44.8

41.9

80.4

78.4

83.4

63.7

63.6

63.9

ANC in 1st trimester

10.8

10.9

10.7

6.3

8.9

4.1

45.0

47.2

41.8

52.1

46.0

57.6

2.1

1.4

2.5

2.5

3.0

2.1

46.7

47.8

45.1

74.6

68.1

80.7

Delivery attendant, %
Physician
Nurse/nurse midwife

63.4

67.6

60.3

44.9

49.5

41.1

1.5

2.2

0.5

24.9

31.6

18.8

Traditional birth attendant

20.3

16.7

23.0

38.9

31.6

44.9

51.4

49.7

53.9

0.0

0.0

0.0

Family/Unattended

14.2

14.3

14.1

13.7

15.9

11.9

0.5

0.4

0.6

0.4

0.3

0.5

Hospital

20.1

26.8

15.1

15.2

16.8

13.9

43.9

43.6

44.3

99.2

99.1

99.3

Clinic

48.2

46.7

49.4

31.5

35.4

28.4

4.2

6.3

1.1

0.1

0.1

0.1

Home/Other

31.7

26.5

35.6

53.2

47.9

57.7

51.9

50.1

54.6

0.7

0.8

0.6

1.0

0.9

1.2

2.0

2.3

1.7

20.6

21.3

19.6

38.6

35.9

41.1

Delivery location, %

Cesarean section, %

Region

South Asia

Characteristic

Belgaum, India

Nagpur, India

Pakistan

Sub-Saharan Africa
Zambia

Kenya

Guatemala

Latin America
Argentina

Intervention clusters

11.3

9.3

23.4

14.4

2.9

9.1

17.2

Control clusters

1.8

1.3

1.5

0.3

0.4

1.0

9.2

Intervention clusters

133 (249.5)

109 (305.3)

172 (226.3)

30 (151.5)

45 (191.5)

57 (164.7)

20 (219.8)

Control clusters

158 (255.7)

84 (329.4)

172 (250.4)

27 (127.4)

27 (142.9)

39 (234.9)

17 (129.8)
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Table 3 ACT intervention effect on antenatal corticosteroid use and 28-day neonatal mortality by site

ACS use among all women %

Neonatal mortality <28 daysa, N (Rate/1000)
Neonatal deaths <5th %tile

Neonatal deaths All births
Intervention clusters

378 (25.8)

221 (29.8)

359 (48.4)

83 (19.6)

103 (17.6)

130 (22.6)

26 (12.4)

Control clusters

369 (22.5)

159 (21.3)

397 (49.8)

76 (13.3)

81 (11.5)

102 (26.1)

27 (11.8)

ACT intervention effect on neonatal mortality < 28 daysa
[RR (95 % CI)b] for intervention versus control
Neonatal deaths <5th %tile

0.96 (0.75, 1.22)

0.94 (0.72, 1.23)

0.89 (0.80, 0.99)

1.43 (0.90, 2.28)

1.30 (0.94, 1.81)

0.75 (0.69, 0.82)

1.60 (0.99, 2.58)

Neonatal deaths All births

1.13 (0.99, 1.27)

1.36 (1.09, 1.71)

0.93 (0.82, 1.07)

1.77 (1.42, 2.20)

1.47 (1.02, 2.12)

0.86 (0.72, 1.03)

1.06 (0.54, 2.09)

a

The denominator for neonatal deaths is live births
Hypotheses test results: Relative Risk (RR) with corresponding 95 % CI and p-values calculated from generalized linear models with generalized estimating equations which account for the cluster-level variance and
are adjusted for randomization strata

b
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14 % in the African sites. Finally, 99.2 % of Argentina
site women delivered in a hospital compared to 20 % or
less in both African sites. Cesarean section rates ranged
2 % or less in the African sites to nearly 39 % in
Argentina.
The metrics of care varied by intervention and control
cluster status for both antenatal care and delivery care.
In Belgaum, India, measures of ANC tended to be better
in the control clusters, while these measures were better
in the intervention clusters in Nagpur, India. Few substantial differences in ANC between the intervention
and control clusters were observed for other sites. In the
Argentinian and both Indian sites, rates of physiciandelivery were higher in the control clusters compared to
the intervention clusters, while Pakistan and Guatemala
had higher physician-delivery rates in the intervention
clusters. Both African sites had low rates (≤3 %) of physician delivery, which were similar across intervention
groups. With the exception of the two African sites which
had lower rates of hospital births among interventions
clusters, the sites generally had higher rates of hospital
deliveries in the intervention clusters compared to the
control clusters (though differences in Argentina were
negligible). In regard to the rates of hospital delivery,
similar trends between the intervention and control
clusters were observed in the sites during the pre-trial
period (data now shown).
Across all sites, the use of ACS was substantially
higher in the intervention compared to the control clusters (Table 3).
The associations between being in the intervention
clusters and 28-day neonatal mortality among the <5th
percentile birth weight infants varied across sites.
(Table 3, Fig. 1) Overall the intervention was associated with no benefit or harmful effect on all < 5th percentile infants, but a reduction in neonatal mortality
among the <5th percentile birth weight infants in
Guatemala (RR 0.75; 95 % CI 0.69–0.82) as well as

Page 6 of 9

Pakistan (RR 0.89; 95 % CI 0.80–0.99) (Fig. 2). The experience of the Guatemala site, which showed the
most favorable outcome, is described in detail elsewhere [Garces A, McClure EM, Figueroa L, et al.: A
multi-faceted intervention including antenatal corticosteroids to reduce neonatal mortality associated with
preterm birth: A case study from the Guatemalan
Western Highlands, forthcoming].
For infants of all birth weights, across all sites the
intervention compared to the control clusters was associated with a significant increase in the risk of neonatal
death (RR 1 · 12, 95 % CI 1.02–1.22, p = 0.0127). When
we stratified by site, this relationship was evident in the
African sites: Zambia (RR 1.77; 95 % CI 1.42–2.20) and
Kenya (RR 1.47; 95 % CI 1.02–2.12), and to a lesser extent in Nagpur, India (RR 1.36; 95 % CI 1.09–1.71). A
marginally significant increase was also seen in Belgaum,
India (RR 1.13; 95 % CI 0.99–1.27) (Table 3; Fig. 2). A
significant association was not seen in the other sites.
We assessed the effect of being in the intervention
compared to the control clusters on pSBI, adjusting for
the pre-trial pSBI rates of the clusters. Being in the intervention clusters was associated with a statistically significant increase in pSBI in the African sites, Zambia (RR:
1.87; 95 % CI: 1.55-2.25) and Kenya (RR 1.90; 95 % CI
1.20–3.02). pSBI was not significantly associated with the
intervention for the other sites. (Fig. 3).

Discussion
ACT is a large randomized trial to assess a program
aimed at increasing ACS use among women at risk of
preterm birth. The trial sites represented diverse LMIC
settings across Latin America, Asia and sub-Saharan
Africa. While there was no overall benefit to being in
the intervention group across the entire study, sites in
Guatemala and Pakistan had a significantly lower neonatal mortality in the intervention compared to the

Fig. 1 The RR of 28-day neonatal mortality among <5th percentile live births comparing the intervention to control clusters by site

Klein et al. Reproductive Health (2016) 13:64
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Fig. 2 The RR of 28-day neonatal mortality comparing the intervention to control clusters among all births by site

control clusters in the targeted (<5th percentile) infants,
while there was no evidence of benefit or harm in < 5th
percentile infants in the other sites.
Among all infants, the sites in Zambia, Kenya, and
Belgaum and Nagpur (India) had a statistically or marginally significant increase in 28-day neonatal mortality in the
intervention compared to the control clusters. The
Zambian and Kenyan sites also had statistically significant increases in the risk of pSBI associated with the
ACT intervention.
Considerable differences in ANC and obstetric care
were found among the sites. Compared to the Asian and
Latin American sites, the two sites in sub-Saharan Africa
had substantially worse indicators of care. Few women
delivered at a health facility, few deliveries were attended
by a physician and the cesarean section rates were low.
Differences in care between the intervention and control
clusters varied by site. While the clusters were stratified
based on neonatal mortality rates prior to randomization,

many of the differences in care observed between the
intervention and control clusters appeared to precede the
initiation of the ACT intervention. Overall, there were no
clear patterns in the relationships between the outcomes
and care when the intervention and control clusters were
compared. For example, 28-day neonatal mortality was
increased in the intervention clusters in Zambia despite
increases in facility-based deliveries in those clusters.
Similarly, the three sites with increased neonatal mortality had heterogeneous rates of skilled birth attendants at delivery. Kenya and Zambia had less care
provided by traditional birth attendants or family birth
attendants in the intervention compared to the control
clusters, but an increase in overall neonatal mortality
associated with the intervention. In the Pakistan site,
where a slight benefit was associated with the intervention, no substantive differences in the processes of care
were evident between the intervention and control
clusters.

Fig. 3 RR of pSBI comparing the intervention to control clusters among all births by site (adjusted for pretrial pSBI rates)
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In contrast, in the Guatemala site, one of the two countries that showed positive effects associated with the intervention, care at delivery was better in the intervention
compared to the control clusters including the use of ACS
(which reached almost 50 % of the target group), delivery
at a hospital or clinic, delivery by a physician and delivery
by cesarean section. The findings in Guatemala are
explored in detail elsewhere [Garces A, McClure EM,
Figueroa L, et al.: A multi-faceted intervention including
antenatal corticosteroids to reduce neonatal mortality
associated with preterm birth: A case study from the
Guatemalan Western Highlands, forthcoming].
The increased risk of pSBI in neonates associated with
the intervention observed in the Kenyan and Zambian
sites are consistent with the harmful effect on neonatal
mortality also seen in the same countries. This finding is
also in agreement with the overall increase in pSBI and
death associated with the intervention reported in another paper of this series [Hibberd PL, Hansen NI,
Wang M, et al.: Trends in the Incidence of Possible Severe Bacterial Infection and Case Fatality Rates in
Rural communities in Sub-Saharan Africa, South Asia
and Latin America, 2010–2013: A multicenter prospective cohort study, forthcoming]. Although these
observations should be considered cautiously, they
strengthen the plausibility that neonatal infection could
have played a role in the observed harmful effect on neonatal mortality.

Conclusions
Across all the sites there was no reduction in neonatal
mortality in the <5th percentile infants. However,
Guatemala and to a lesser extent Pakistan had significant
reductions in neonatal mortality in these infants.
Guatemala, which had better indicators of care compared
to some of the other sites and also in the intervention
compared to the control clusters, showed benefit in the
intervention compared to the control clusters in the targeted birth weight group. On the other hand, Kenya and
Zambia showed a significant increase in neonatal mortality, as well as in suspected neonatal infection. Neonatal infection should be further investigated as a main outcome
in future research studies.
These observations are intended as exploratory in
nature and trends were not consistent across all sites.
Because of the importance of identifying effective interventions to reduce neonatal mortality in the geographic
areas with highest burden, further research is needed to
define the impact of ACS across diverse settings in LMIC.
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